COVID-19 Conversation: FDA Listening Session, April 17, 2020

LUNGevity spoke with the Thoracic Oncology Team from the US Food and Drug Administration's Oncology Center of Excellence to discuss the impact of the COVID-19 pandemic on lung cancer clinical trials and the details of the new Guidance issued by the Agency. Lung cancer patients had the opportunity to speak directly with the FDA to have their questions answered and concerns addressed.

These April 17 videos feature Dr. Richard Pazdur, Director of the FDA’s Oncology Center of Excellence, and Dr. Harpreet Singh, Director, Division of Oncology 2, along with members of the FDA’s thoracic oncology team. In part 2 of the video, a panel of lung cancer patients ask questions. A list of COVID-19 resources from the FDA appears below the videos.

Download a transcript of the discussion here.

FDA COVID-19 Resources for Patients